This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKNegative Net Change GILDNegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
by Kinjel Shah
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change ADVMNo Net Change
pharmaceuticals
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
by Zacks Equity Research
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
JNJNegative Net Change MRKNegative Net Change UTHRNegative Net Change
pharmaceuticals
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
NVONegative Net Change VNDANegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
by Kinjel Shah
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
AZNNegative Net Change JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
by Zacks Equity Research
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms
JNJNegative Net Change ALKSNegative Net Change BAYRYPositive Net Change FOLDNegative Net Change
biotechnology medical pharmaceuticals
Pharma ETF (FTXH) Hits New 52-Week High
by Sanghamitra Saha
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
FTXHNegative Net Change
etfs pharmaceuticals
Bull of the Day: Collegium Pharmaceutical (COLL)
by Shaun Pruitt
This medical stock has been seeing strong momentum but is still cheaply valued and may serve as a further hedge against recent market jitters.
COLLNegative Net Change
earnings investing medical pharmaceuticals
Top Research Reports for Microsoft, Amazon.com & Eli Lilly
by Mark Vickery
Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.
AMZNPositive Net Change MSFTPositive Net Change LLYNegative Net Change YUMPositive Net Change SCHWNegative Net Change CNQNegative Net Change
computers pharmaceuticals retail
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
by Zacks Equity Research
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
RHHBYNegative Net Change LLYNegative Net Change ALKSNegative Net Change BAYRYPositive Net Change
medical pharmaceuticals
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
NVONegative Net Change ADMAPositive Net Change ARQTNegative Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
by Kinjel Shah
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change CDTXPositive Net Change
pharmaceuticals
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
by Kinjel Shah
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change
pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
GSKNegative Net Change ADMAPositive Net Change ALECPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
by Sundeep Ganoria
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
BIIBNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Top 3 Genomics Stocks to Consider for Your Portfolio
by Ekta Bagri
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
ILMNPositive Net Change PACBPositive Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change SANANegative Net Change
biotechnology gene-editing genetics genomics medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
by Zacks Equity Research
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
JNJNegative Net Change LLYNegative Net Change ADVMNo Net Change
pharmaceuticals
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
by Zacks Equity Research
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
RHHBYNegative Net Change ALKSNegative Net Change SRPTPositive Net Change CRMDPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
by Zacks Equity Research
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMYNegative Net Change JNJNegative Net Change CYTKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus
by Santanu Roy
Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.
CATNegative Net Change UNHNegative Net Change JNJNegative Net Change MPositive Net Change CACINegative Net Change UNFINegative Net Change CORNegative Net Change MNSTNegative Net Change MTZNegative Net Change LAKENo Net Change FNLPFPositive Net Change NOBLNegative Net Change
construction consumer-staples industrial-products medical pharmaceuticals precious-metals retail
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
by Kanishka Das
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
PFENegative Net Change NVONegative Net Change MRKNegative Net Change CDTXPositive Net Change
pharmaceuticals
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
MRKNegative Net Change MRNAPositive Net Change CDTXPositive Net Change SMMTNegative Net Change
pharmaceuticals
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
by Kinjel Shah
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
JNJNegative Net Change NVONegative Net Change LLYNegative Net Change ADVMNo Net Change
pharmaceuticals